
Dosing
In resectable and metastatic EGFRm NSCLC
Convenient, once-daily dosing that may fit into their routine1
One 80-mg tablet once a day
Pill image is not actual size.
In resectable disease: Administer TAGRISSO in the adjuvant setting until disease recurrence, unacceptable toxicity, or for up to 3 years. Patients in the ADAURA trial are treated with TAGRISSO for 3 years or until disease recurrence or unacceptable toxicity1*
In metastatic disease: Administer TAGRISSO until disease progression or unacceptable toxicity1*
*Select patients for treatment with TAGRISSO based on the presence of EGFR exon 19 deletions or exon 21 L858R mutations.
TAGRISSO dosing is the same in both the adjuvant and metastatic settings1
For patients who have difficulty swallowing pills1
Dose modifications1
EGFRm, epidermal growth factor receptor mutation positive; L858R, exon 21 leucine 858 arginine substitution; NG, nasogastric; NSCLC, non-small cell lung cancer.
Reference: TAGRISSO [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.
TAGRISSO is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test
TAGRISSO is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test
TAGRISSO is indicated for the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy
For additional information, please see the complete Prescribing Information, including Patient Information.
You may report side effects related to AstraZeneca products by clicking here.